Paper of the Month - Volume 10 Issue 2

0 rating

Management of Lack and Loss of Response to Anti-Tumor Necrosis Factor Therapy

Anne Christine W Vos, Herma H Fidder, MD, PhD, Gijs R van den Brink, MD, PhD, and Daniel W Hommes, MD, PhD

Until the late 1990s, the treatment of Crohn’s disease predominantly involved the use of steroids, 5-aminosalicylates (5-ASAs), and antimetabolites. However, patients often fail to achieve and maintain response and remission with these therapies. The majority of patients eventually need corticosteroids to manage the disease, and these are associated with potentially serious side effects [1].



READER POLL

IBD poll 2
Which IBD patients do you consider to be most at risk of lymphoma?






Powered by NetPolls

SUBMIT AN ARTICLE